Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease
Objective: To reappraise the role of the µ opioid receptor as a therapeutic target for L-DOPA-induced dyskinesia. Background: Parkinson’s disease (PD) is commonly treated with…Zonisamide ameliorates levodopa-induced dyskinesia via striatal cholinergic system in a rat model of Parkinson’s disease
Objective: To investigate the difference in results according to the mode of levodopa administration and the effect of zonisamide (ZNS) on striatal cholinergic system, we…Toning down SPNs to improve motor responses to dopaminergic stimulation in Parkinson’s disease
Objective: This study was aimed at examining whether decreasing the baseline SPN firing frequency towards the low activity found in normal conditions reduces LID. Background:…The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: We seek to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…STN-DBS programing for dyskinesia: a case report
Objective: To investigate the effect of STN stimulation on different types of dyskinesia and programming strategy. Background: Long-term use of levodopa or dopamine agonists often…Memantine induced dyskinesia in Alzheimer’s disease
Objective: There is only little evidence for memantine induced dyskinesia in Alzheimer’s disease. We present a patient with Alzheimer’s disease who developed choreatic dyskinesia as a result…LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset
Objective: We aim to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…Inhibitory Repetitive Transcranial Magnetic Stimulation of Pre-Supplementary Motor Area Improves Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To prove the causal role of pre-supplementary motor area (preSMA) in levodopa-induced dyskinesia using an interventional brain stimulation approach that targets abnormal preSMA activity. Background:…Moving ear syndrome secondary to bromopride and response to botulinum toxin
Objective: Report a case of a rare drug-induced movement disorder, the moving ear syndrome, describe its phenomenology and its treatment with botulinum toxin Background: Since…The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)
Objective: The DYSCOVER study will be the first interventional, randomized study to evaluate the comparative effectiveness of levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 44
- Next Page »